Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Rhea-AI Summary
Centessa Pharmaceuticals (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on developing transformational medicines, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York. The company's management team will engage in a fireside chat on Tuesday, September 9th at 4:50 PM ET.
Investors and interested parties can access the live audio webcast and archived recording through the "Events & Presentations" section on Centessa's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction 51 Alerts
On the day this news was published, CNTA declined 7.87%, reflecting a notable negative market reaction. Argus tracked a trough of -9.1% from its starting point during tracking. Our momentum scanner triggered 51 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $189M from the company's valuation, bringing the market cap to $2.22B at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. A fireside chat is scheduled for Tuesday, September 9th at 4:50 PM ET.
The live audio webcast of this event, as well as an archived recording, will be available under the “Events & Presentations” tab on the investor relations section of the Centessa Pharmaceuticals website at https://investors.centessa.com/.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals, plc is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver medicines that are transformational for patients. We are pioneering a new class of potential therapies within our orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, and fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. For more information, visit www.centessa.com, which does not form part of this release.
Contact:
Kristen K. Sheppard, Esq.
SVP of Investor Relations
investors@centessa.com
FAQ
When is Centessa Pharmaceuticals (CNTA) presenting at the Morgan Stanley Healthcare Conference 2025?
How can investors access Centessa Pharmaceuticals' (CNTA) Morgan Stanley conference presentation?
What type of company is Centessa Pharmaceuticals (CNTA)?
Where is the Morgan Stanley Healthcare Conference 2025 being held?
